美国与欧洲甲状腺协会成员对甲状腺眼病管理的调查
该横断面电子调查于2021年6月2日至30日开展,252名美国与欧洲甲状腺协会成员参与(应答率15%),227人完成。调查发现甲状腺眼病管理存在明显地域差异:欧洲受访者治疗轻度活动性甲状腺眼病更多使用硒,北美受访者治疗中重度活动性甲状腺眼病更倾向首选替妥木单抗,而欧洲和其他地区受访者更倾向静脉糖皮质激素。
要点
- 轻度活动性甲状腺眼病:欧洲受访者使用硒的比例为73%(96/132),高于北美32%(20/62)和其他地区24%(8/33)。
- 中重度活动性甲状腺眼病:北美受访者首选替妥木单抗37%(23/62),欧洲和其他地区首选静脉糖皮质激素分别为73%(96/132)和42%(14/33)。
- 受访者对甲状腺眼病管理最关注的三个问题为治疗费用31.3%(71/227)、缺乏有效治疗19.8%(45/227)和难以预测甲状腺眼病是否发生18.9%(43/227)。
核心结论
- 甲状腺眼病管理存在明显的地域实践差异。
- 临床医生对甲状腺眼病管理的担忧要求持续研究更有效的治疗、甲状腺眼病预测工具以及政策变化以改善新疗法的可负担性。
研究设计与样本
- 2021年6月2日至6月30日对美国与欧洲甲状腺协会成员进行的横断面电子调查,252名合格参与者开始调查(应答率15%),227人完成。
主要发现
- 受访者多为男性(50.2%,114/227)、白人(79.7%,181/227)、以甲状腺为关注点的内分泌科医生(66.1%,150/227)、在三级学术中心执业(46.7%,106/227)、过去12个月诊治10例及以上甲状腺眼病患者(40.5%,92/227),并报告所在机构没有多学科甲状腺眼病门诊(52.8%,120/227)。
- 多数受访者报告过去10年每年新发甲状腺眼病病例数没有变化(47.5%,108/227),且甲状腺眼病患者是在甲状腺功能亢进症管理过程中被发现的(41.8%,95/227)。
- 轻度活动性甲状腺眼病:欧洲受访者使用硒的比例为73%(96/132),北美受访者为32%(20/62),其他地区受访者为24%(8/33)。
- 中重度活动性甲状腺眼病:北美受访者首选替妥木单抗的比例为37%(23/62),欧洲受访者首选静脉糖皮质激素的比例为73%(96/132),其他地区受访者首选静脉糖皮质激素的比例为42%(14/33)。
- 在合并控制不佳糖尿病的中重度活动性甲状腺眼病患者中,上述治疗偏好没有变化;三个地理类别受访者对于视神经病变和计划妊娠的女性均偏好静脉糖皮质激素。
关键数值与推荐
- 受访者对甲状腺眼病管理认为「非常重要」的三大担忧:甲状腺眼病治疗费用(31.3%,71/227)、缺乏有效甲状腺眼病治疗(19.8%,45/227)、难以预测甲状腺眼病是否会发生(18.9%,43/227)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The thyroid eye disease (TED) treatment landscape is rapidly evolving. How new treatment options have impacted practice is unknown. Methods: We conducted a cross-sectional electronic survey of American and European Thyroid Association members between June 2 and June 30, 2021. The survey included TED questions about resources for its management, index cases for different severities and presentations of TED, barriers for the management of TED, and participants' concerns about TED. We classified respondents into three geographic categories: North America, Europe, or other regions. Results: Two hundred fifty-two eligible participants started the survey (15% response rate), and 227 completed it. Participants were mostly men (50.2%, 114/227), white (79.7%, 181/227), endocrinologists with a thyroid focus (66.1%, 150/227), practicing in a tertiary academic center (46.7%, 106/227), caring for 10 or more TED patients over the last 12 months (40.5%, 92/227), and reported not having a multidisciplinary TED clinic in their institution (52.8%, 120/227). The majority reported that new TED cases per annum have not changed in the past 10 years (47.5%, 108/227), and that TED patients are found in practice during the management of hyperthyroidism (41.8%, 95/227). For mild active TED, participants from Europe reported a higher use of selenium (73%[96/132] vs. 32%[20/62] of respondents from North America and 24%[8/33] of respondents from other regions). For moderate-to-severe active TED, there was a modest preference for teprotumumab as first-line therapy (37%, 23/62) among North American participants and intravenous (IV) steroids (73%[96/132], and 42%[14/33]) for participants from Europe and other regions, respectively. These treatment preferences did not change in patients with moderate-to-severe active TED with poorly controlled diabetes. In contrast, participants from the three geographic categories preferred IV steroids for optic neuropathy and women planning pregnancy. The three top "very important" concerns about TED management according to participants were: the cost of TED treatment (31.3%, 71/227), lack of effective TED treatments (19.8%, 45/227), and difficulty in predicting whether TED will develop (18.9%, 43/227). Conclusions: There is a marked geographic practice variation in the management of TED. Clinicians' concerns about TED management demand ongoing research on more effective treatment, TED predictive tools, and policy changes to improve the affordability of new TED therapies.
引用
- Brito JP, Nagy EV, Singh Ospina N, et al. A Survey on the Management of Thyroid Eye Disease Among American and European Thyroid Association Members. Thyroid. 2022. PMID: 35946071. doi:10.1089/thy.2022.0172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。